Sobi Reports Positive Phase 3 Results for Pozdeutinurad in Gout
Sobi reports positive Phase 3 REDUCE-2 results for investigational gout treatment pozdeutinurad, demonstrating sustained serum urate reduction over 12 months.
Placebo Group | 30/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy